Company Profile
Atea Stock Price, News & Analysis
- Ticker:
- AVIR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.99 USD (+5.05%)
Close
Last updated: August 6, 2026
342M USD
Market cap
Why the stock is moving
The latest company update was “Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026”. AVIR changed 1.06% and closed at $4.75 on Aug 5, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Antiviral Therapeutics Company
Atea Pharmaceuticals develops oral antiviral combinations for serious viral diseases.
Hepatitis C Regimen
The lead regimen combines nucleotide polymerase inhibitor bemnifosbuvir with NS5A inhibitor ruzasvir as a short-duration, ribavirin-free treatment for hepatitis C.
Global Phase 3 Program
C-BEYOND covers North America, while C-FORWARD evaluates the same regimen outside North America.
Hepatitis E Pipeline
AT-587 is an earlier oral candidate being developed as a potential first-in-class treatment for hepatitis E.
Future catalysts
Topline results from the Phase 3 C-BEYOND hepatitis C study are expected in mid-2026.
C-FORWARD enrollment is expected to complete in mid-2026, with topline results around year-end 2026.
A Phase 1 study of AT-587 in hepatitis E is expected to begin around mid-2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Atea (AVIR)?
Atea (AVIR) most recently closed at 4.99 USD, a +5.05% move versus the previous session.
What is the market cap of Atea (AVIR)?
Atea currently has a market capitalization of 342M USD on BioPharmSignal.
What does Atea do?
Antiviral Therapeutics Company Atea Pharmaceuticals develops oral antiviral combinations for serious viral diseases. Hepatitis C Regimen The lead regimen combines nucleotide polymerase inhibitor bemnifosbuvir with NS5A inhibitor ruzasvir as a short-duration, ribavirin-free treatment for hepatitis C. Global Phase 3 Program C-BEYOND covers North America,...
On which exchange is AVIR stock listed?
Atea (AVIR) is associated with NASDAQ, United States, Biopharma.
What is AT-587?
A Phase 1 study of AT-587 in hepatitis E is expected to begin around mid-2026.
Which conditions is Atea targeting with AT-587?
A Phase 1 study of AT-587 in hepatitis E is expected to begin around mid-2026.
How does Atea describe recent progress with AT-587?
A Phase 1 study of AT-587 in hepatitis E is expected to begin around mid-2026.
What is bemnifosbuvir?
Hepatitis C Regimen The lead regimen combines nucleotide polymerase inhibitor bemnifosbuvir with NS5A inhibitor ruzasvir as a short-duration, ribavirin-free treatment for hepatitis C.